Search
Clinician Ordering Portal
Scientific Evidence
Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma
May 2021
To determine how results from a prognostic 40-gene expression profiling (40-GEP) test would impact clinician management decisions and how their choices would align with a National Comprehensive Cancer Network (NCCN) compliant, risk-directed management plan for high-risk cutaneous squamous cell carcinoma (cSCC).
Publication: Curr Med Res Opin
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma
Apr 2020
To develop and validate a gene expression profile (GEP) test for predicting risk for metastasis in localized, high-risk cSCC with the goal of improving risk-directed patient management.
Publication: JAAD
Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical practice guideline
Dec 2019
This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).
Publication: Pract Radiat Oncol
Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists
Oct 2019
To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.
Publication: JDD
Guidelines of care for the management of cutaneous squamous cell carcinoma
Feb 2018
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC.
Publication: J Am Acad Dermatol
The treatment of actinic keratoses — the rule rather than the exception
Nov 2017
This work highlights a critical aspect of the physician-patient relationship—communication. As expected, the findings suggest that the verbiage used to describe actinic keratoses (AKs) can affect the patient’s decision to pursue treatment. Interestingly, regardless of how the question was framed, most patients preferred to treat these lesions.
Publication: JAMA Dermatol
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma
Dec 2013
To compare American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC), and Brigham and Women's Hospital (BWH) tumor (T) staging systems for cutaneous squamous cell carcinoma and validate BWH staging against prior data.
Publication: Journal of Clinical Oncology
AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for MOHS micrographic surgery: A report of the American Academy of Dermatology, American College of MOHS Surgery, American Society for Dermatologic Surgery Association, and the American Society for MOHS Surgery
Oct 2012
The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics.
Publication: J Am Acad Dermatol